Surgery Clinical Trial
— ALIVEOfficial title:
The Role of Left Atrial Fibrosis in Mitral Valve Repair Surgery (ALIVE Trial)
Rationale: Patients with mitral valve insufficiency suffer from left atrial remodeling. Atrial fibrosis is part of this remodeling process. The presence of atrial fibrosis is associated with adverse events. Currently, mitral valve repair surgery is the ultimate treatment for severe primary mitral valve insufficiency. The main indications and timing for surgery are severe mitral valve insufficiency with symptoms or left ventricular dysfunction. However, the role of atrial fibrosis in this process remains undetermined despite its well-recognized clinical implications. Characterization of atrial fibrosis patterns in mitral valve insufficiency patients might be potentially valuable for the indication and timing of mitral valve repair surgery in order to improve clinical outcomes. To date, however, mitral valve insufficiency patients suffering from left atrial remodeling have hardly been studied using these new imaging techniques. Therefore, the investigators intend to combine advanced cardiac MRI and post-processing techniques prior to and after mitral valve repair surgery to gain more insight in the clinical implications of atrial fibrosis in this patient population. It is hypothesized that the atrial fibrosis surface area paradoxically will increase after mitral valve surgery because of global shrinkage of the left atrium caused by the reversed remodeling process. As a consequence, more frequently atrial fibrosis related events including (paroxysmal) atrial fibrillation, may be observed in these patients. Objective: To assess the effects of (reduced) volume overload on the left atrial wall texture (presence, amount and location of atrial fibrosis) and associated geometry and function in patients with mitral valve insufficiency, prior to and after mitral valve repair surgery. Study design: Single center pilot study. Study population: The research population consists of mitral valve insufficiency patients scheduled for elective surgical mitral valve repair (N=20) according to the current European guideline criteria.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | December 2023 |
Est. primary completion date | July 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Patients that meet the criteria for elective mitral valve repair surgery according to the European clinical guidelines (class I recommendation); - Symptomatic, chronic severe mitral valve insufficiency due to degenerative valve disease with a left ventricular ejection fraction >30%. - Asymptomatic, chronic severe mitral valve insufficiency due to degenerative valve disease with a left ventricular ejection fraction <60% and/or a left ventricular end-systolic diameter >45 mm. Exclusion Criteria: - not able to provide written informed consent. - under the age of 18. - with a history of cardiac surgery - with atrial fibrillation - with any comorbidity besides mitral valve insufficiency. - with claustrophobia or any other contra-indication for magnetic resonance imaging |
Country | Name | City | State |
---|---|---|---|
Netherlands | AmsterdamUMC | Amsterdam | Noord-Holland |
Lead Sponsor | Collaborator |
---|---|
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Severity of mitral valve insufficiency prior to surgery (regurgitation volume on MRI) | Severity of mitral valve insufficiency prior to surgery (defined as regurgitation volume in ml calculated using difference between left ventricular stroke volume (LVSV) and forward flow) | 2 weeks before surgery | |
Primary | Severity of mitral valve insufficiency after surgery (regurgitation volume on MRI) | Severity of mitral valve insufficiency after surgery (defined as regurgitation volume in ml calculated using difference between left ventricular stroke volume (LVSV) and forward flow) | 3 months after surgery | |
Primary | Left atrial remodelling prior to surgery (left atrial volume on MRI) | Left atrial volume (ml) measured by multislice volumetric method on MRI | 2 weeks before surgery | |
Primary | Left atrial remodelling after surgery (left atrial volume on MRI) | Left atrial volume (ml) measured by multislice volumetric method on MRI | 3 months after surgery | |
Primary | Left atrial remodelling prior to surgery (left atrial sphericity on MRI) | Calculated left atrial sphericity by using ratio of transverse and longitudinal diameters of the left atrium | 2 weeks before surgery | |
Primary | Left atrial remodelling after surgery (left atrial sphericity on MRI) | Calculated left atrial sphericity by using ratio of transverse and longitudinal diameters of the left atrium | 3 months after surgery | |
Primary | Left atrial remodelling prior to surgery (estimated wall tension) | Estimated wall tension using a calculation combining left atrial wall thickness, left atrial radius and pulmonary wedge pressure. Wall thickness and radius will be measured on MRI. Pulmonary wedge pressure will be measured by using a Swan-Ganz catheter during surgery | 2 weeks before surgery | |
Primary | Left atrial remodelling after surgery (estimated wall tension) | Estimated wall tension using a calculation combining left atrial wall thickness, left atrial radius and pulmonary wedge pressure. Wall thickness and radius will be measured on MRI. Pulmonary wedge pressure will be measured by using a Swan-Ganz catheter during surgery | 3 months after surgery | |
Primary | Presence and distribution patterns of LA fibrosis prior to surgery (quantification of fibrosis surface) | Quantification of fibrosis surface will be assessed by using dedicated software Cricle ADAS which is able to segment the left atrial wall and recognize fibrotic tissue by means of late gadolinium enhancement | 2 weeks before surgery | |
Primary | Presence and distribution patterns of LA fibrosis after surgery (quantification of fibrosis surface) | Quantification of fibrosis surface will be assessed by using dedicated software Cricle ADAS which is able to segment the left atrial wall and recognize fibrotic tissue by means of late gadolinium enhancement | 3 months after surgery | |
Primary | Presence and distribution patterns of LA fibrosis prior to surgery (geometric distribution of fibrosis) | Geometric distribution of fibrosis in the left atrium will be assessed using dedicated software Circle ADAS. The software is able to segment the left atrial and define the three-dimensional geometric distribution of fibrotic tissue | 2 weeks before surgery | |
Primary | Presence and distribution patterns of LA fibrosis after surgery (geometric distribution of fibrosis) | Geometric distribution of fibrosis in the left atrium will be assessed using dedicated software Circle ADAS. The software is able to segment the left atrial and define the three-dimensional geometric distribution of fibrotic tissue | 3 months after surgery | |
Primary | Blood flow patterns in the left atrium prior to surgery (flow velocity) | Blood flow patterns in the left atrium will be assessed by measuring flow velocity using synthetic velocity fields as well as Poiseuille flow. This will be done with dedicated software Circle | 2 weeks before surgery | |
Primary | Blood flow patterns in the left atrium after surgery (flow velocity) | Blood flow patterns in the left atrium will be assessed by measuring flow velocity using synthetic velocity fields as well as Poiseuille flow. This will be done with dedicated software Circle | 3 months after surgery | |
Primary | Blood flow patterns in the left atrium prior to surgery (kinetic energy) | Kinetic energy of the blood flow patterns will be measured by using dedicated software Circle by means of advanced 4D flow CRM techniques defining global kinetic energy | 2 weeks before surgery | |
Primary | Blood flow patterns in the left atrium after surgery (kinetic energy) | Kinetic energy of the blood flow patterns will be measured by using dedicated software Circle by means of advanced 4D flow CRM techniques defining global kinetic energy | 3 months after surgery | |
Secondary | Change of fibrosis associated biomarkers derived from blood samples (prior to surgery versus after surgery) - NT-proBNP | NT-proBNP | 2 weeks before surgery and 3 months after surgery | |
Secondary | Change of fibrosis associated biomarkers derived from blood samples (prior to surgery versus after surgery) - TGF-ß | TGF-ß | 2 weeks before surgery and 3 months after surgery | |
Secondary | Change of fibrosis associated biomarkers derived from blood samples (prior to surgery versus after surgery) - TNF-alfa | TNF-alfa | 2 weeks before surgery and 3 months after surgery | |
Secondary | Change of fibrosis associated biomarkers derived from blood samples (prior to surgery versus after surgery) - Galectin-3 | Galectin-3 | 2 weeks before surgery and 3 months after surgery | |
Secondary | Change of fibrosis associated biomarkers derived from blood samples (prior to surgery versus after surgery) - MMS | MMS | 2 weeks before surgery and 3 months after surgery | |
Secondary | Change of fibrosis associated biomarkers derived from blood samples (prior to surgery versus after surgery) - Angiotensin II | Angiotensin II | 2 weeks before surgery and 3 months after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT03213314 -
HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies
|
N/A | |
Enrolling by invitation |
NCT05534490 -
Surgery and Functionality in Older Adults
|
N/A | |
Recruiting |
NCT04792983 -
Cognition and the Immunology of Postoperative Outcomes
|
||
Terminated |
NCT04612491 -
Pre-operative Consultation on Patient Anxiety and First-time Mohs Micrographic Surgery
|
||
Recruiting |
NCT06397287 -
PROM Project Urology
|
||
Recruiting |
NCT04444544 -
Quality of Life and High-Risk Abdominal Cancer Surgery
|
||
Completed |
NCT04204785 -
Noise in the OR at Induction: Patient and Anesthesiologists Perceptions
|
N/A | |
Completed |
NCT03432429 -
Real Time Tissue Characterisation Using Mass Spectrometry REI-EXCISE iKnife Study
|
||
Completed |
NCT04176822 -
Designing Animated Movie for Preoperative Period
|
N/A | |
Recruiting |
NCT05370404 -
Prescribing vs. Recommending Over-The-Counter (PROTECT) Analgesics for Patients With Postoperative Pain:
|
N/A | |
Not yet recruiting |
NCT05467319 -
Ferric Derisomaltose/Iron Isomaltoside and Outcomes in the Recovery of Gynecologic Oncology ERAS
|
Phase 3 | |
Recruiting |
NCT04602429 -
Children's Acute Surgical Abdomen Programme
|
||
Completed |
NCT03124901 -
Accuracy of Noninvasive Pulse Oximeter Measurement of Hemoglobin for Rainbow DCI Sensor
|
N/A | |
Completed |
NCT04595695 -
The Effect of Clear Masks in Improving Patient Relationships
|
N/A | |
Recruiting |
NCT06103136 -
Maestro 1.0 Post-Market Registry
|
||
Completed |
NCT05346588 -
THRIVE Feasibility Trial
|
Phase 3 | |
Completed |
NCT04059328 -
Novel Surgical Checklists for Gynecologic Laparoscopy in Haiti
|
||
Recruiting |
NCT03697278 -
Monitoring Postoperative Patient-controlled Analgesia (PCA)
|
N/A |